Fluorescence of Amphotericin B-Deoxycholate (Fungizone) Monomers and Aggregates and the Effect of Heat-Treatment

Langmuir ◽  
2007 ◽  
Vol 23 (17) ◽  
pp. 8718-8725 ◽  
Author(s):  
Robin Stoodley ◽  
Kishor M. Wasan ◽  
Dan Bizzotto
Keyword(s):  
Heat Treatment ◽  
Amphotericin B ◽  
Amphotericin B Deoxycholate

scholarly journals Activity of a Heat-Induced Reformulation of Amphotericin B Deoxycholate (Fungizone) against Leishmania donovani

1999 ◽  
Vol 43 (2) ◽  
pp. 390-392 ◽  
Author(s):  
C. Petit ◽  
V. Yardley ◽  
F. Gaboriau ◽  
J. Bolard ◽  
S. L. Croft
Keyword(s):  
Heat Treatment ◽  
Amphotericin B ◽  
Infected Mouse ◽  
Mammalian Cells ◽  
Leishmania Donovani ◽  
Peritoneal Macrophages ◽  
Amphotericin B Deoxycholate ◽  
Mouse Peritoneal Macrophages

ABSTRACT The heat treatment of amphotericin B deoxycholate (Fungizone), which was previously shown to induce superaggregation and decrease the toxicity of the drug to mammalian cells, increased its activity againstLeishmania donovani in BALB/c mice, whereas it reduced its toxicity. Heat treatment preserved the activity of Fungizone againstL. donovani HU3-infected mouse peritoneal macrophages.

scholarly journals Comparative Drug Disposition, Urinary Pharmacokinetics, and Renal Effects of Multilamellar Liposomal Nystatin and Amphotericin B Deoxycholate in Rabbits

2003 ◽  
Vol 47 (12) ◽  
pp. 3917-3925 ◽  
Author(s):  
Andreas H. Groll ◽  
Diana Mickiene ◽  
Vidmantas Petraitis ◽  
Ruta Petraitiene ◽  
Raul M. Alfaro ◽  
...  
Keyword(s):  
Total Dose ◽  
Amphotericin B ◽  
Drug Disposition ◽  
Fungal Infections ◽  
Standard Dose ◽  
Concentration Data ◽  
Drug Concentrations ◽  
Amphotericin B Deoxycholate ◽  
Dose Dependent Decrease ◽  
Dose Dependent

ABSTRACT The comparative drug dispositions, urinary pharmacokinetics, and effects on renal function of multilamellar liposomal nystatin (LNYS; Nyotran) and amphotericin B deoxycholate (DAMB; Fungizone) were studied in rabbits. Drug concentrations were determined by high-performance liquid chromatography as total concentrations of LNYS and DAMB. In comparison to a standard dose of 1 mg of DAMB/kg of body weight, therapeutic dosages of LNYS, i.e., 2, 4, and 6 mg/kg, resulted in escalating maximum concentrations (C max) (17 to 56μ g/ml for LNYS versus 3.36 μg/ml for DAMB; P< 0.001) and values for the area under the concentration-time curve from 0 to 24 h (AUC0-24) (17 to 77μ g · h/ml for LNYS versus 12μ g · h/ml for DAMB; P < 0.001) in plasma but a significantly faster total clearance from plasma (0.117 to 0.080 liter/h/kg for LNYS versus 0.055 liter/h/kg for DAMB; P = 0.013) and a ≤8-fold-smaller volume of distribution at steady state (P = 0.002). Urinary drug concentration data revealed a ≥10-fold-higher C max (16 to 10 μg/ml for LNYS versus 0.96μ g/ml for DAMB; P = 0.015) and a 4- to 7-fold-greater AUC0-24 (63 to 35μ g · h/ml for LNYS versus 8.9μ g · h/ml for DAMB; P = 0.015) following the administration of LNYS, with a dose-dependent decrease in the dose-normalized AUC0-24 in urine (P= 0.001) and a trend toward a dose-dependent decrease in renal clearance. Except for the kidneys, the mean concentrations of LNYS in liver, spleen, and lung 24 h after dosing were severalfold lower than those after administration of DAMB (P,<0.002 to <0.001). Less than 1% each of the total dose of LNYS was recovered from the kidneys, liver, spleen, and lungs; in contrast, a quarter of the total dose was recovered from the livers of DAMB-treated animals. LNYS had dose-dependent effects on glomerular filtration and distal, but not proximal, renal tubular function which did not exceed those of DAMB at the highest investigated dosage of 6 mg/kg. The results of this experimental study demonstrate fundamental differences in the dispositions of LNYS and DAMB. Based on its enhanced urinary exposure, LNYS may offer a therapeutic advantage in systemic fungal infections involving the upper and lower urinary tracts that require therapy with antifungal polyenes.

scholarly journals Life‐Threatening Adverse Event After Amphotericin B Lipid Complex Treatment in a Patient Treated Previously with Amphotericin B Deoxycholate

1998 ◽  
Vol 26 (4) ◽  
pp. 1016-1016 ◽  
Author(s):  
J. Garnacho‐Montero ◽  
C. Ortiz‐Leyba ◽  
J. L. García Garmendia ◽  
F. J. Jiménez Jiménez
Keyword(s):  
Adverse Event ◽  
Amphotericin B ◽  
Complex Treatment ◽  
Lipid Complex ◽  
Amphotericin B Deoxycholate ◽  
Life Threatening ◽  
Amphotericin B Lipid Complex

Effect of amphotericin B‐deoxycholate (Fungizone) on the mitochondria of Wistar rats' renal proximal tubules cells

2021 ◽  
Author(s):  
Shehab Ahmed Alenazi ◽  
Ekramy Elmorsy ◽  
Ayat Al‐Ghafari ◽  
Amr El‐Husseini
Keyword(s):  
Amphotericin B ◽  
Wistar Rats ◽  
Proximal Tubules ◽  
Renal Proximal Tubules ◽  
Amphotericin B Deoxycholate

Reply: Continuous Infusion of Amphotericin B Deoxycholate for the Treatment of Life-ThreateningCandidaInfections

2013 ◽  
Vol 188 (8) ◽  
pp. 1033-1034
Author(s):  
Didier Dreyfuss ◽  
Jean-Damien Ricard ◽  
Stéphane Gaudry
Keyword(s):  
Continuous Infusion ◽  
Amphotericin B ◽  
Amphotericin B Deoxycholate

Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients

2004 ◽  
Vol 77 (2) ◽  
pp. 232-237 ◽  
Author(s):  
Richard H. Drew ◽  
Elizabeth Dodds Ashley ◽  
Daniel K. Benjamin ◽  
R. Duane Davis ◽  
Scott M. Palmer ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Lung Transplant ◽  
Antifungal Prophylaxis ◽  
Transplant Recipients ◽  
Lipid Complex ◽  
Amphotericin B Deoxycholate ◽  
Amphotericin B Lipid Complex ◽  
Comparative Safety ◽  
Lung Transplant Recipients

Effect of variation in infrrsion time and macrophage blockade on organ uptake of amphotericin B-deoxycholate

1991 ◽  
Vol 28 (6) ◽  
pp. 919-924 ◽  
Author(s):  
Lee C. Edmonds ◽  
Laslie Davidson ◽  
Joseph S. Bertino
Keyword(s):  
Amphotericin B ◽  
Organ Uptake ◽  
Amphotericin B Deoxycholate

scholarly journals A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis

2018 ◽  
Vol 37 (10) ◽  
pp. 992-998 ◽  
Author(s):  
Daniel K. Benjamin ◽  
David A. Kaufman ◽  
William W. Hope ◽  
P. Brian Smith ◽  
Antonio Arrieta ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Invasive Candidiasis ◽  
Phase 3 ◽  
Amphotericin B Deoxycholate

scholarly journals Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis

2018 ◽  
Vol 62 (7) ◽  
Author(s):  
Katharine E. Stott ◽  
Justin Beardsley ◽  
Sarah Whalley ◽  
Freddie Mukasa Kibengo ◽  
Nguyen Thi Hoang Mai ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Rate Constant ◽  
Cryptococcal Meningitis ◽  
Drug Exposure ◽  
Meta Analysis ◽  
Central Compartment ◽  
Order Rate Constant ◽  
Peripheral Compartment ◽  
First Order ◽  
Amphotericin B Deoxycholate

ABSTRACT There is a limited understanding of the population pharmacokinetics (PK) and pharmacodynamics (PD) of amphotericin B deoxycholate (DAmB) for cryptococcal meningitis. A PK study was conducted in n = 42 patients receiving DAmB (1 mg/kg of body weight every 24 h [q24h]). A 2-compartment PK model was developed. Patient weight influenced clearance and volume in the final structural model. Monte Carlo simulations estimated drug exposure associated with various DAmB dosages. A search was conducted for trials reporting outcomes of treatment of cryptococcal meningitis patients with DAmB monotherapy, and a meta-analysis was performed. The PK parameter means (standard deviations) were as follows: clearance, 0.03 (0.01) × weight + 0.67 (0.01) liters/h; volume, 0.82 (0.80) × weight + 1.76 (1.29) liters; first-order rate constant from central compartment to peripheral compartment, 5.36 (6.67) h−1; first-order rate constant from peripheral compartment to central compartment, 9.92 (12.27) h−1. The meta-analysis suggested that the DAmB dosage explained most of the heterogeneity in cerebrospinal fluid (CSF) sterility outcomes but not in mortality outcomes. Simulations of values corresponding to the area under concentration-time curve from h 144 to h 168 (AUC144–168) resulted in median (interquartile range) values of 5.83 mg · h/liter (4.66 to 8.55), 10.16 mg · h/liter (8.07 to 14.55), and 14.51 mg · h/liter (11.48 to 20.42) with dosages of 0.4, 0.7, and 1.0 mg/kg q24h, respectively. DAmB PK is described adequately by a linear model that incorporates weight with clearance and volume. Interpatient PK variability is modest and unlikely to be responsible for variability in clinical outcomes. There is discordance between the impact that drug exposure has on CSF sterility and its impact on mortality outcomes, which may be due to cerebral pathology not reflected in CSF fungal burden, in addition to clinical variables.

Sign in / Sign up

Export Citation Format

Share Document